Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo

Ding Ai, Yi Fu, Deliang Guo, Hiromasa Tanaka, Nanping Wang, Chaoshu Tang, Bruce D. Hammock, John Y J Shyy, Yi Zhu

Research output: Contribution to journalArticle

118 Citations (Scopus)

Abstract

Epoxyeicosatrienoic acids (EETs), as metabolites of arachidonic acid, may function as antihypertensive and antiatherosclerotic mediators for vasculature. EETs are degraded by soluble epoxide hydrolase (sEH). Pharmacological inhibition and genetic ablation of sEH have been shown to increase the level of EETs, and treating angiotensin II (Ang ll)-infused hypertension rats with sEH-selective inhibitors increased the levels of EETs, with attendant decrease in systolic blood pressure. To elucidate the mechanisms by which Ang II regulates sEH expression, we treated human umbilical vein endothelial cells (ECs) and bovine aortic ECs with Ang II and found increased sEH expression at both the mRNA and protein levels. Transient transfection assays showed that the activity of the human sEH promoter was increased in ECs in response to Ang II. Further analysis of the promoter region of the sEH gene demonstrated that treatment with Ang II, like overexpression of c-Jun/ c-Fos, activates the sEH promoter through an AP-1-binding motif. The binding of c-Jun to the AP-1 site of the sEH promoter was confirmed by chromatin immunoprecipitation assays. In contrast, adenovirus overexpression of the dominant-negative mutant of c-Jun significantly attenuated the effects of Ang II on sEH induction. An elevated level of sEH was found in the aortic intima of both spontaneously hypertensive rats and Ang ll-infused Wistar rats. Blocking Ang II binding to Ang II receptor 1 by losartan abolished the sEH induction. Thus, AP-1 activation is involved in the transcriptional up-regulation of sEH by Ang II in ECs, which may contribute to Ang ll-induced hypertension.

Original languageEnglish (US)
Pages (from-to)9018-9023
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume104
Issue number21
DOIs
StatePublished - May 22 2007

Fingerprint

Epoxide Hydrolases
Vascular Endothelium
Angiotensin II
Up-Regulation
Transcription Factor AP-1
Endothelial Cells
In Vitro Techniques
Blood Pressure
Hypertension
Losartan
Chromatin Immunoprecipitation
Human Umbilical Vein Endothelial Cells
Inbred SHR Rats
Genetic Promoter Regions
Arachidonic Acid
Adenoviridae
Human Activities
Antihypertensive Agents
Transfection
Wistar Rats

Keywords

  • AP-1
  • Arachidonic acid
  • Endothelial cells
  • Hypertension
  • Promoter

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. / Ai, Ding; Fu, Yi; Guo, Deliang; Tanaka, Hiromasa; Wang, Nanping; Tang, Chaoshu; Hammock, Bruce D.; Shyy, John Y J; Zhu, Yi.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 104, No. 21, 22.05.2007, p. 9018-9023.

Research output: Contribution to journalArticle

Ai, Ding ; Fu, Yi ; Guo, Deliang ; Tanaka, Hiromasa ; Wang, Nanping ; Tang, Chaoshu ; Hammock, Bruce D. ; Shyy, John Y J ; Zhu, Yi. / Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. In: Proceedings of the National Academy of Sciences of the United States of America. 2007 ; Vol. 104, No. 21. pp. 9018-9023.
@article{15a0f20f8c184cc6ae63204a95a53908,
title = "Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo",
abstract = "Epoxyeicosatrienoic acids (EETs), as metabolites of arachidonic acid, may function as antihypertensive and antiatherosclerotic mediators for vasculature. EETs are degraded by soluble epoxide hydrolase (sEH). Pharmacological inhibition and genetic ablation of sEH have been shown to increase the level of EETs, and treating angiotensin II (Ang ll)-infused hypertension rats with sEH-selective inhibitors increased the levels of EETs, with attendant decrease in systolic blood pressure. To elucidate the mechanisms by which Ang II regulates sEH expression, we treated human umbilical vein endothelial cells (ECs) and bovine aortic ECs with Ang II and found increased sEH expression at both the mRNA and protein levels. Transient transfection assays showed that the activity of the human sEH promoter was increased in ECs in response to Ang II. Further analysis of the promoter region of the sEH gene demonstrated that treatment with Ang II, like overexpression of c-Jun/ c-Fos, activates the sEH promoter through an AP-1-binding motif. The binding of c-Jun to the AP-1 site of the sEH promoter was confirmed by chromatin immunoprecipitation assays. In contrast, adenovirus overexpression of the dominant-negative mutant of c-Jun significantly attenuated the effects of Ang II on sEH induction. An elevated level of sEH was found in the aortic intima of both spontaneously hypertensive rats and Ang ll-infused Wistar rats. Blocking Ang II binding to Ang II receptor 1 by losartan abolished the sEH induction. Thus, AP-1 activation is involved in the transcriptional up-regulation of sEH by Ang II in ECs, which may contribute to Ang ll-induced hypertension.",
keywords = "AP-1, Arachidonic acid, Endothelial cells, Hypertension, Promoter",
author = "Ding Ai and Yi Fu and Deliang Guo and Hiromasa Tanaka and Nanping Wang and Chaoshu Tang and Hammock, {Bruce D.} and Shyy, {John Y J} and Yi Zhu",
year = "2007",
month = "5",
day = "22",
doi = "10.1073/pnas.0703229104",
language = "English (US)",
volume = "104",
pages = "9018--9023",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "21",

}

TY - JOUR

T1 - Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo

AU - Ai, Ding

AU - Fu, Yi

AU - Guo, Deliang

AU - Tanaka, Hiromasa

AU - Wang, Nanping

AU - Tang, Chaoshu

AU - Hammock, Bruce D.

AU - Shyy, John Y J

AU - Zhu, Yi

PY - 2007/5/22

Y1 - 2007/5/22

N2 - Epoxyeicosatrienoic acids (EETs), as metabolites of arachidonic acid, may function as antihypertensive and antiatherosclerotic mediators for vasculature. EETs are degraded by soluble epoxide hydrolase (sEH). Pharmacological inhibition and genetic ablation of sEH have been shown to increase the level of EETs, and treating angiotensin II (Ang ll)-infused hypertension rats with sEH-selective inhibitors increased the levels of EETs, with attendant decrease in systolic blood pressure. To elucidate the mechanisms by which Ang II regulates sEH expression, we treated human umbilical vein endothelial cells (ECs) and bovine aortic ECs with Ang II and found increased sEH expression at both the mRNA and protein levels. Transient transfection assays showed that the activity of the human sEH promoter was increased in ECs in response to Ang II. Further analysis of the promoter region of the sEH gene demonstrated that treatment with Ang II, like overexpression of c-Jun/ c-Fos, activates the sEH promoter through an AP-1-binding motif. The binding of c-Jun to the AP-1 site of the sEH promoter was confirmed by chromatin immunoprecipitation assays. In contrast, adenovirus overexpression of the dominant-negative mutant of c-Jun significantly attenuated the effects of Ang II on sEH induction. An elevated level of sEH was found in the aortic intima of both spontaneously hypertensive rats and Ang ll-infused Wistar rats. Blocking Ang II binding to Ang II receptor 1 by losartan abolished the sEH induction. Thus, AP-1 activation is involved in the transcriptional up-regulation of sEH by Ang II in ECs, which may contribute to Ang ll-induced hypertension.

AB - Epoxyeicosatrienoic acids (EETs), as metabolites of arachidonic acid, may function as antihypertensive and antiatherosclerotic mediators for vasculature. EETs are degraded by soluble epoxide hydrolase (sEH). Pharmacological inhibition and genetic ablation of sEH have been shown to increase the level of EETs, and treating angiotensin II (Ang ll)-infused hypertension rats with sEH-selective inhibitors increased the levels of EETs, with attendant decrease in systolic blood pressure. To elucidate the mechanisms by which Ang II regulates sEH expression, we treated human umbilical vein endothelial cells (ECs) and bovine aortic ECs with Ang II and found increased sEH expression at both the mRNA and protein levels. Transient transfection assays showed that the activity of the human sEH promoter was increased in ECs in response to Ang II. Further analysis of the promoter region of the sEH gene demonstrated that treatment with Ang II, like overexpression of c-Jun/ c-Fos, activates the sEH promoter through an AP-1-binding motif. The binding of c-Jun to the AP-1 site of the sEH promoter was confirmed by chromatin immunoprecipitation assays. In contrast, adenovirus overexpression of the dominant-negative mutant of c-Jun significantly attenuated the effects of Ang II on sEH induction. An elevated level of sEH was found in the aortic intima of both spontaneously hypertensive rats and Ang ll-infused Wistar rats. Blocking Ang II binding to Ang II receptor 1 by losartan abolished the sEH induction. Thus, AP-1 activation is involved in the transcriptional up-regulation of sEH by Ang II in ECs, which may contribute to Ang ll-induced hypertension.

KW - AP-1

KW - Arachidonic acid

KW - Endothelial cells

KW - Hypertension

KW - Promoter

UR - http://www.scopus.com/inward/record.url?scp=34547468357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547468357&partnerID=8YFLogxK

U2 - 10.1073/pnas.0703229104

DO - 10.1073/pnas.0703229104

M3 - Article

C2 - 17495027

AN - SCOPUS:34547468357

VL - 104

SP - 9018

EP - 9023

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 21

ER -